Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
XB-010 by Exelixis for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
XB-010 is under clinical development by Exelixis and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to GlobalData,...
Data Insights
XB-010 by Exelixis for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
XB-010 is under clinical development by Exelixis and currently in Phase I for Head And Neck Squamous Cell Carcinoma (HNSC)....